Stentys : Report on the General Meeting of June 4, 2018

STENTYS: Report on the General Meeting of June 4, 2018

Approval of all ordinary resolutions

PARIS - June 4, 2018 - 10.00 pm CEST - STENTYS (FR0010949404 - STNT), a medical technology company commercializing the Xposition S self-apposing coronary stent, informs its shareholders that the Annual General Meeting held on June 4 on the second call approved all of the ordinary resolutions. The extraordinary resolutions were not put to the vote, as the required quorum was not reached.

Upcoming financial publication

Revenues for the second quarter of 2018: Wednesday July 11, 2018

About STENTYS

STENTYS develops and commercializes innovative solutions for the treatment of patients with complex artery disease. STENTYS' Self-Apposing® drug-eluting stents (DES) are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition problems associated with conventional stents. The APPOSITION clinical trials for the treatment of acute myocardial infarction showed a very low mortality rate at one year and a faster arterial healing compared to conventional stents. The company's product portfolio also includes MiStent SES® and Serpentis, two innovative coronary DES for routine interventions, and is marketed through STENTYS' commercial network in Europe, the Middle East, Asia and Latin America.

Additional information is available atwww.stentys.com

STENTYS	NewCap
André Lerebours	Investor Relations / Strategic Communications
CFO	Dusan Oresansky / Alexia Faure
Tel.: [phone]	Tel.: [phone]
[e-mail]	[e-mail]
STENTYS is listed on Compartment C of Euronext Paris
ISIN: FR0010949404 - Ticker: STNT
Forward-looking Statements

This press release contains forward-looking statements about the Company that are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward-looking statements involve known and unknown risks which may cause the Company's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company's products, market acceptance of the Company's products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section 4 "Risk Factors" of the Company's 2016 Registration Document (document de référence) filed with the French Autorité des Marchés Financiers (AMF) on November 29, 2017 under number D.17-1084.

Page 1 of 1